Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · November 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Oncogenic FGFR alterations drive the development of multiple cancers. However, acquired resistance to clinically approved inhibitors mediated by gatekeeper and molecular brake mutations poses a major therapeutic challenge. Herein, we describe the structure-based discovery of (Z)-3-(amino(phenyl)methylene)indolin-2-one derivatives as potent covalent pan-FGFR inhibitors. The representative compound, 9v, displayed high potency against FGFR1/2/3/4 (IC50 = 8.6, 5.4, 4.4, and 6.9 nM, respectively) and potent antiproliferative effects across a panel of FGFR-driven cancer cell lines (IC50 = 0.3−6.1 nM). Notably, 9v retained high efficacy against common resistance mutations, including the gatekeeper (FGFR1 V561M, FGFR2 V564F, and FGFR3 V555M) and “molecular brake” (FGFR2 N549K) variants, with IC50 values of <0.1 nM. Covalent modification of FGFR3 by 9v was confirmed through MALDI-TOF-MS and LC−MS/MS-based site mapping. Furthermore, 9v exhibited significant antitumor efficacy in an RT112/84 bladder cancer xenograft model, providing a promising strategy to overcome resistance in FGFR-targeted therapy.